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Comparing the 
incomparable: studies of 
echocardiographic 
rheumatic heart disease 
prevalence  
The summary of the research about 
rheumatic heart disease prevalence 
by Martina Rothenbühler and 
colleagues (December, 2014, issue)1 
highlights the substantial burden of 
disease in endemic regions across the 
globe. However, the large diﬀ erences 
between echocardiography prevalence 
studies used in the meta-analysis 
preclude meaningful analysis and 
comparison (as evident in the 
heterogeneity I² scores). In the studies 
included in the meta-analysis, various 
echocardiographic diagnostic criteria 
are used, each with diﬀ erent diagnostic 
features or disease categorisation. The 
diﬀ erences between these criteria can 
affect the estimation of rheumatic 
heart disease prevalence (especially 
of silent or borderline disease), even 
when applied in the same clinical 
population.2,3 Further, the included 
studies had varying methods and 
designs. Some undertook portable 
echocardiography only, others 
portable echocardiography followed 
by hospital echocardiography. 
There is a risk, identiﬁ ed by Beaton 
and colleagues,4 that portable 
echocardiography alone might result 
in many false positive diagnoses of 
rheumatic heart disease and thereby 
overstate estimates of disease 
prevalence.
Taken together, we conside r that it 
is diﬃ  cult to compare the prevalence 
rates from these studies, a concern 
identiﬁ ed by Roberts and colleagues.5 
We believe that the comparison of 
these echocardiography studies 
calls attention to two key areas 
that necessitate further research. 
First, the development and then 
validation of universally accepted 
and clinically relevant criteria for 
echocardiographic diagnosis of 
rheumatic heart disease;2 and second, 
the undertaking of diagnostic studies 
(not cross-sectional prevalence 
studies) comparing portable with 
hospital echocardiography. Research 
into these issues will help us better 
assess the disease burden of rheumatic 
heart disease and the suitability of 
echocardiography for screening.
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